On October 22, 2024 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, reported its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually (Press release, Xenetic Biosciences, OCT 22, 2024, View Source [SID1234647312]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
Abstract Number: 765
Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
For more information about the conference, visit www.sitcancer.org/2024.